Quest Diagnostics Finalizes $500M Senior Notes Offering Due 2036
DGX sits 19% above its 52-week low of $164.65.
Summary
Quest Diagnostics has finalized the terms for a $500 million offering of 5.000% Senior Notes due 2036, with proceeds intended for general corporate purposes including debt repayment.
Key Events · Financing and Capital Events · DGX
-
Finalized Debt Offering
Quest Diagnostics finalized the terms for a $500 million offering of 5.000% Senior Notes due 2036.
-
Maturity and Yield
The notes have a maturity date of June 30, 2036, and an issue price of 98.751% of the principal amount, resulting in a yield of 5.158%.
-
Use of Proceeds
Proceeds are designated for general corporate purposes, including the repayment of existing indebtedness, specifically mentioning the 3.45% Senior Notes due June 1, 2026.
-
Credit Ratings
The notes carry investment-grade ratings of Baa1 (Moody's), BBB+ (S&P), and BBB+ (Fitch).
Analysis · DGX · Industrial Applications And Services
This Free Writing Prospectus (FWP) finalizes the terms of Quest Diagnostics' $500 million senior notes offering, initiated via a prior registration statement. The issuance of 5.000% notes maturing in 2036 is a significant financing event, representing a strategic move to manage the company's capital structure. The proceeds are earmarked for general corporate purposes, including the refinancing of existing indebtedness, such as the 3.45% Senior Notes due in June 2026. This proactive debt management, coupled with the company's recent strong financial performance and ongoing share repurchase program, indicates a stable financial position and prudent capital allocation.
At the time of this filing, DGX was trading at $196.63 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $21.8B. The 52-week trading range was $164.65 to $213.50. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.